• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

IJERPH, Vol. 17, Pages 2787: Clinical Manifestations and Causes of Anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland
rek Anaphylaxis is most commonly defined as an acute, severe, potentially life-threatening systemic hypersensitivity reaction. Current expert consensus has defined anaphylaxis as a serious reaction that is rapid in onset and can be fatal, and is a severe, potentially life-threatening systemic hypersensitivity reaction that is still rarely diagnosed. For safety reasons, patients should visit an allergologist to identify potential causes of this reaction. There are no data from other health care centres in Poland presenting characteristics of anaphylactic reactions. Clinical manifestations of anaphylaxis should be analys...
Source: International Journal of Environmental Research and Public Health - April 16, 2020 Category: Environmental Health Authors: Poziomkowska-G ęsicka Kurek Tags: Article Source Type: research

Action Plan to Reach the Global Availability of Adrenaline Auto-Injectors.
Abstract Adrenaline is the first-line treatment for anaphylaxis and, therefore, listed as an essential medication for the treatment of anaphylaxis by the World Health Organization (WHO). However, the availability of auto-injector (AAI) forms for use in the first-aid treatment is limited to only 32% of all 195-world countries, mostly high-income countries. The key issues leading to the lack of availability of AAIs include cost but also national regulations, lack of regional evidence about the value of epinephrine and the limited accurate data about the epidemiology of anaphylaxis. For these reasons, regional and in...
Source: Journal of Investigational Allergology and Clinical Immunology - November 13, 2018 Category: Allergy & Immunology Authors: Kase Tanno L, Demoly P, Joint Allergy Academies Tags: J Investig Allergol Clin Immunol Source Type: research

An update on the impact of food allergy on anxiety and quality of life
Purpose of review: Food allergies have become more common, and management involves dietary avoidance that can impair quality of life. Patients and families must manage the daily risk of anaphylaxis at each meal. The purpose of this review is to describe the impact of food allergies on quality of life and to provide an update on new developments in food allergy management, particularly peanut allergy. Recent findings: Food allergy requires careful avoidance of common and ubiquitous dietary allergens. Living with food allergy is associated with annual economic costs in excess of $4000 per child, in addition to risks of anxi...
Source: Current Opinion in Pediatrics - July 13, 2017 Category: Pediatrics Tags: OFFICE PEDIATRICS: Edited by Henry H. Bernstein Source Type: research

Sarah Jessica Parker Ends Mylan Partnership Over EpiPen Price Hike
Sarah Jessica Parker has ended her relationship with the controversial pharmaceutical company Mylan.  In May, the actress joined forces with the makers of the EpiPen through a campaign called Anaphylaxis for Reel. At the time, Parker urged awareness for life-threatening allergies and revealed that the issue is personal for her because her 13-year-old son, James Wilke Broderick has a severe peanut and hazelnut allergy.  But following reports that the company raised the price of their standard two-pack of EpiPens from $100 in 2009 to $600 in 2016, Parker publicly cut ties and condemned the price hike. &ld...
Source: Healthy Living - The Huffington Post - August 25, 2016 Category: Consumer Health News Source Type: news